Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-07

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Psoriasis is a chronic inflammatory skin disease (chronic and recurrent) which is influenced by various factors, namely genetics, immunological processes, and environmental triggers such as infection, obesity, smoking, and drugs.

The provision of probiotic Lactobacillus plantarum IS-10506, an Indonesian original probiotic strain, is expected to be an effective, safe, and affordable alternative for psoriasis treatment for psoriasis patients in Indonesia.

This study aimed to evaluate changes in gut microbiota profile, cytokines IL-17, TNF-a, IL-10, Foxp3, and disease severity of psoriasis vulgaris patients after supplementation with Lactobacillus plantarum IS-10506. The results of this study are expected to be the basis for the use of Lactobacillus plantarum IS-10506 in the therapy of psoriasis vulgaris which is included in the Clinical Practice Guide in Indonesia, which will ultimately help improve the quality of life of psoriasis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial

NCT07194200

Psoriasis Lactobacillus Plantarum

RECRUITING PHASE2

Intervention Study to Evaluate a Probiotic in Mild to Moderate Psoriasis Patients

NCT02576197

Psoriasis

COMPLETED NA

Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

NCT00563524

Psoriasis

COMPLETED PHASE1

TSO for Plaque Psoriasis

NCT02011269

Plaque Psoriasis

WITHDRAWN PHASE2

A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy

NCT06643260

Plaque Psoriasis

NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Psoriasis is a chronic inflammatory skin disease (chronic and recurrent) which is influenced by various factors, namely genetics, immunological processes, and environmental triggers such as infection, obesity, smoking, and drugs. Psoriasis can increase the incidence of other diseases such as joint disorders, cardiovascular disorders, and psychological. Symptoms of psoriasis on the skin are red, well-defined plaques covered with thick, white, layered scales. The incidence of psoriasis is quite large, known to affect 0.09 - 11.4% of the world's population with rates varying between regions. Data in Indonesia is estimated that there are 2-6 million psoriasis sufferers in 2010, with a prevalence range of 1-3% in several teaching hospitals. During the period from 2016 to 2018, psoriasis vulgaris patients in the outpatient unit of RSUD Dr. Soetomo Surabaya recorded as many as 208 or 0.46% of all skin patients.

One of the mechanisms of psoriasis is abnormalities in Treg cells (cells that play a role in expressing Foxp3), resulting in an imbalance in the immune system with the dominance of T helper 1 (Th1) and T helper 17 (Th17) cells. In addition, the composition of the gut microbiota (collection of bacteria) in psoriasis patients is different from that of healthy people. The composition of the gut microbiota can be influenced by race, geography, and eating habits. Until now there has been no report on the intestinal microbiota profile of psoriasis patients in Indonesia.

The provision of probiotic Lactobacillus plantarum IS-10506, is expected to be an effective, safe, and affordable alternative for psoriasis treatment for psoriasis patients in Indonesia. Lactobacillus plantarum IS-10506 is produced from Dadih, a traditional fermented milk from West Sumatra, Indonesia. This probiotic is expected to be most compatible with the composition of the gut microbiota of Indonesians because it comes from an environment with similar exposure to pathogenic bacteria.

This study aimed to evaluate changes in gut microbiota profile, cytokines IL-17, TNF-a, IL-10, Foxp3, and disease severity of psoriasis vulgaris patients after supplementation with Lactobacillus plantarum IS-10506. The results of this study are expected to be the basis for the use of Lactobacillus plantarum IS-10506 in the therapy of psoriasis vulgaris which is included in the Clinical Practice Guide in Indonesia, which will ultimately help improve the quality of life of psoriasis patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A double blinded randomized clinical trial using a prospective cohort method in psoriasis vulgaris patients with purposive sampling.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Probiotic and placebo packaging are made the same, and drug code is randomized by pharmacy

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

In the treatment group, intervention was given in the form of standard therapy and probiotic Lactobacillus plantarum IS 10605 in the amount of 2x1010 CFU for 12 weeks.

Group Type ACTIVE_COMPARATOR

Lactobacillus Plantarum IS-10506

Intervention Type DRUG

Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU

Placebo Group

In the placebo group, intervention was given in the form of standard therapy and placebo 2x1 sachets for 12 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets

Healty Control Group

Healthy control group was not given any treatment. Stool samples were taken to examine the gut microbiota profile.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lactobacillus Plantarum IS-10506

Indonesian original probiotic, given in capsule form with a dose of 2 x 1010 CFU

Intervention Type DRUG

Placebo

Placebo is an empty drug, given in capsule form with a dose of 2x1 sachets

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Probiotic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Psoriasis vulgaris patients with or without treatment
2. Mild to moderate degree
3. Age 18-70 years old
4. Willing to give informed consent

1. Undiagnosed as Psoriasis
2. Body mass index (BMI) is matched with the patient group
3. Age 18-70 years old
4. Willing to give Informed Consent

Exclusion Criteria

1. Patients on systemic treatment with corticosteroids, methotrexate, cyclosporine, or biologic agents within 3 months prior to sampling
2. Take oral antibiotics, laxatives, and proton pump inhibitors (PPI) within 14 days before stool sampling
3. Suffering from severe systemic disease, diarrhea
4. Pustular psoriasis patients
5. Take probiotics within 30 days before stool sampling

1. Patients on systemic treatment with corticosteroids, methotrexate, cyclosporine, or biologic agents within 3 months before stool sampling
2. Take oral antibiotics, laxatives, and proton pump inhibitors (PPI) within 14 days before stool sampling
3. Suffering from severe systemic disease, diarrhea

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes